Mergers & acquisitions
UndergroundStocks.com, an elite wall street independent small cap media group with a history of bringing lucrative opportunities, Reports on Omni Health, Inc.
The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II.
This is the second extension that has been filed, this time delaying it until June 3. The companies indicate it is because U.S. authorities are taking longer than expected to review the deal.
The project company Belina is running an innovative project in early phase and is developing a product for treatment of breast cancer.
Eur 140 m bridge loan was drawn to secure evotec’s value chain expansion by successful acquisition of aptuit in august 2017
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
The combination of the two companies will create a leader in cell-based cancer immunotherapy, Kiadis said. It also further expands Kiadis’ toehold in the United States.
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a longer time.
Somerset, NJ-based CRO Catalent announced it is acquiring Baltimore-based Paragon BioServices for $1.2 billion.
Although it was probably not in serious jeopardy, Bristol-Myers Squibb’s shareholders voted today to approve the acquisition of Celgene Corporation for about $74 billion.
PRESS RELEASES